1: Clin Nutr. 2007 Mar 12; [Epub ahead of print] Links
Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: A pilot study.
Bruzzese E,
Raia V,
Spagnuolo MI,
Volpicelli M,
De Marco G,
Maiuri L,
Guarino A.
Department of Pediatrics, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy.
BACKGROUND & AIMS: Probiotics reduce intestinal inflammation in children with cystic fibrosis (CF). We want to determine the effects of Lactobacillus GG (LGG) on pulmonary exacerbations in CF. METHODS: A prospective, randomized, placebo-controlled, cross-over study was performed. Nineteen children received LGG for 6 months and then shifted to oral rehydration solution (ORS) for 6 months. In parallel nineteen received ORS and then shifted to LGG. Main outcome parameters were: incidence of pulmonary exacerbations and of hospital admissions, forced expiratory volume (FEV(1)), and modifications of body weight. RESULTS: Patients treated with LGG showed a reduction of pulmonary exacerbations (Median 1 vs. 2 , range 4 vs. 4, median difference 1, CI 95% 0.5-1.5; p=0.0035) and of hospital admissions (Median 0 vs. 1, range 3 vs. 2, median difference 1, CI95% 1.0-1.5; p=0.001) compared to patients treated with ORS. LGG resulted in a greater increase in FEV(1) (3.6%+/-5.2 vs. 0.9%+/-5; p=0.02) and body weight (1.5kg+/-1.8 vs. 0.7kg+/-1.8; p=0.02). CONCLUSIONS: LGG reduces pulmonary exacerbations and hospital admissions in patients with CF. These suggest that probiotics may delay respiratory impairment and that a relationship exists between intestinal and pulmonary inflammation.
While your doctor might not know about this study, now you do!!!!
Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: A pilot study.
Bruzzese E,
Raia V,
Spagnuolo MI,
Volpicelli M,
De Marco G,
Maiuri L,
Guarino A.
Department of Pediatrics, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy.
BACKGROUND & AIMS: Probiotics reduce intestinal inflammation in children with cystic fibrosis (CF). We want to determine the effects of Lactobacillus GG (LGG) on pulmonary exacerbations in CF. METHODS: A prospective, randomized, placebo-controlled, cross-over study was performed. Nineteen children received LGG for 6 months and then shifted to oral rehydration solution (ORS) for 6 months. In parallel nineteen received ORS and then shifted to LGG. Main outcome parameters were: incidence of pulmonary exacerbations and of hospital admissions, forced expiratory volume (FEV(1)), and modifications of body weight. RESULTS: Patients treated with LGG showed a reduction of pulmonary exacerbations (Median 1 vs. 2 , range 4 vs. 4, median difference 1, CI 95% 0.5-1.5; p=0.0035) and of hospital admissions (Median 0 vs. 1, range 3 vs. 2, median difference 1, CI95% 1.0-1.5; p=0.001) compared to patients treated with ORS. LGG resulted in a greater increase in FEV(1) (3.6%+/-5.2 vs. 0.9%+/-5; p=0.02) and body weight (1.5kg+/-1.8 vs. 0.7kg+/-1.8; p=0.02). CONCLUSIONS: LGG reduces pulmonary exacerbations and hospital admissions in patients with CF. These suggest that probiotics may delay respiratory impairment and that a relationship exists between intestinal and pulmonary inflammation.
While your doctor might not know about this study, now you do!!!!